Used as a potent inhibitor in targeted cancer therapies, particularly in the treatment of certain tyrosine kinase-driven tumors. It interferes with signaling pathways involved in cell proliferation and survival, especially those associated with epidermal growth factor receptor (EGFR) and related kinases. Its structure allows selective binding to mutant forms of these receptors, making it effective in cancers like non-small cell lung carcinoma. The compound is studied for its ability to overcome resistance seen with earlier generation inhibitors, providing a therapeutic option in resistant or relapsed cases. It is also explored in combination therapies to enhance antitumor efficacy and improve patient outcomes.